Clinical Trial Update: A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 study of CCX140-B in subjects with primary FSGS and nephrotic syndrome was terminated. Results have been posted on 2024-02-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Nephrotic Syndrome

Drugs mentioned

• CCX140-B (CCX140-B)

Snippet

Sponsor: Amgen | Conditions: Focal Segmental Glomerulosclerosis | Phase 2 | Status: TERMINATED | Results posted: 2024-02-06